The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
BACKGROUND: Approximately 40% of primary biliary cholangitis (PBC) patients exhibit poor response to ursodeoxycholic acid (UDCA) and prognosis, referred to as refractory PBC. There is an urgent need to explore new treatment approaches for this patient population…